ONCAlert | AstraZeneca: Pioneers in Ovarian Cancer

Latest NewsMORE >>

Results of an investigation presented at the 2017 American Urological Association Annual Meeting indicate that resistance to docetaxel and cabazitaxel (Jevtana) in patients with castration-resistant prostate cancer (CRPC) is mediated by a common mechanism, overexpression of the ABCB1 gene.1 The study authors further concluded that inhibiting this gene with antiandrogen therapy, such as enzalutamide (Xtandi) and bicalutamide (Casodex), could increase the effectivity of taxane-based therapies in patients with CRPC.

Latest JournalAll Journals >>

Copyright © TargetedOnc 2017 Intellisphere, LLC. All Rights Reserved.